The Vascular Endothelial Growth Factor Receptor (VEGFR) and Cancer

Cancer continues to maintain its importance as a pathological event whose incidence continues to increase. Since the source of pathophysiology is multifaceted, it is one of the popular topics that pharmaceutical and medicinal chemists attach importance to in their studies. In recent studies, when the concept of cancer is considered, it has been observed that it is associated with the mechanism of vascular formation and the mechanisms of action of drugs. Thus, the mechanism of angiogenesis and EGF and VGF systemic pathways that play a great factor in angiogenesis have been elucidated. Inhibition of these systems was targeted while designing drugs and VEGFR (Vascular Endothelial Growth Receptors) emerged. The aim of this study is to compile the types of VEGFR, their relationship with cancer and the mechanisms of action of clinically used drugs approved by various authorities and to enable the readers of this review to recognize the specificities in targets in VEGFR inhibitor design.